🇺🇸 FDA
Pipeline program

Anti-SEMA4D Monoclonal Antibody VX15/2503

17-001570

Phase 1 mab terminated

Quick answer

Anti-SEMA4D Monoclonal Antibody VX15/2503 for Metastatic Melanoma is a Phase 1 program (mab) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
VACCINEX, INC.
Indication
Metastatic Melanoma
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials